• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血脂异常的联合治疗：安全性及监管考量

Combination therapy for dyslipidemia: safety and regulatory considerations.

作者信息

Davidson Michael H

机构信息

Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA.

出版信息

Am J Cardiol. 2002 Nov 20;90(10B):50K-60K. doi: 10.1016/s0002-9149(02)02970-3.

DOI:10.1016/s0002-9149(02)02970-3
PMID:12467940
Abstract

The use of combination therapy is an effective way to manage dyslipidemia in patients with coronary artery disease (CAD). However, combination therapy is not a frequently used strategy in the treatment of CAD. Aggressive lipid-altering therapy often requires the use of combination therapy involving statins in conjunction with niacin, fibric-acid derivatives, ezetimibe, or bile acid resins. Yet, safety concerns regarding the combination of statins with other lipid-altering drugs and patient acceptance of combination therapy have influenced its application in the treatment of CAD. This article discusses several safety and regulatory considerations for the use of combination therapy for dyslipidemia.

摘要

联合治疗是管理冠状动脉疾病（CAD）患者血脂异常的有效方法。然而，联合治疗在CAD治疗中并非常用策略。积极的调脂治疗通常需要使用他汀类药物与烟酸、贝特类衍生物、依折麦布或胆汁酸树脂联合的联合治疗。然而，他汀类药物与其他调脂药物联合使用的安全性问题以及患者对联合治疗的接受程度影响了其在CAD治疗中的应用。本文讨论了血脂异常联合治疗使用中的一些安全性和监管方面的考虑因素。

相似文献

1
Combination therapy for dyslipidemia: safety and regulatory considerations.血脂异常的联合治疗：安全性及监管考量
Am J Cardiol. 2002 Nov 20;90(10B):50K-60K. doi: 10.1016/s0002-9149(02)02970-3.
2
Use of combination therapy for dyslipidemia: a lipid clinic approach.血脂异常联合治疗的应用：脂质门诊治疗方法
Am J Cardiol. 2002 Nov 20;90(10B):44K-49K. doi: 10.1016/s0002-9149(02)02969-7.
3
LDL reduction: how low should we go and is it safe?低密度脂蛋白降低：我们应降至多低，这样安全吗？
Curr Cardiol Rep. 2008 Nov;10(6):481-7. doi: 10.1007/s11886-008-0076-3.
4
The rationale for combination therapy.联合治疗的基本原理。
Am J Cardiol. 2002 Nov 20;90(10B):2K-7K. doi: 10.1016/s0002-9149(02)02966-1.
5
Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.降低低密度脂蛋白胆固醇：他汀类药物、依泽替米贝、胆汁酸螯合剂及联合用药：疗效与安全性比较
Endocrinol Metab Clin North Am. 2009 Mar;38(1):79-97. doi: 10.1016/j.ecl.2008.11.007.
6
Combination therapy for combined dyslipidemia.混合性血脂异常的联合治疗。
Am J Cardiol. 2002 Nov 20;90(10B):21K-29K. doi: 10.1016/s0002-9149(02)02968-5.
7
[Treatment of dyslipidemia: how and when to combine lipid lowering drugs].[血脂异常的治疗：如何以及何时联合使用降脂药物]
Arq Bras Endocrinol Metabol. 2006 Apr;50(2):344-59. doi: 10.1590/s0004-27302006000200021. Epub 2006 May 23.
8
Managing dyslipidemia in the high-risk patient.高危患者血脂异常的管理。
Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. doi: 10.1016/s0002-9149(02)02229-4.
9
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.低密度脂蛋白胆固醇水平为5：联合药物治疗低密度脂蛋白胆固醇的益处与风险
Prev Cardiol. 2010 Spring;13(2):69-71. doi: 10.1111/j.1751-7141.2009.00052.x.
10
Lipid-lowering effects of ezetimibe and simvastatin in combination.依折麦布与辛伐他汀联合使用的降脂效果。
Expert Rev Cardiovasc Ther. 2011 Feb;9(2):131-45. doi: 10.1586/erc.10.179.

引用本文的文献

1
Lipid-Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-Blind, Parallel, Multicenter, Phase 3 Clinical Trial.依折麦布与5毫克阿托伐他汀对原发性高胆固醇血症或混合性血脂异常患者的降脂效果及安全性：一项随机、双盲、平行、多中心、3期临床试验
Clin Cardiol. 2025 May;48(5):e70138. doi: 10.1002/clc.70138.
2
A comparative study of the effect of green tea and sour tea on blood pressure and lipid profile in healthy adult men.绿茶和酸茶对健康成年男性血压和血脂影响的比较研究。
ARYA Atheroscler. 2017 May;13(3):109-116.
3
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
匹伐他汀联合依折麦布治疗急性冠状动脉综合征合并血脂异常患者的低密度脂蛋白胆固醇靶向治疗：HIJ-PROPER研究，一项前瞻性、开放标签、随机试验
Eur Heart J. 2017 Aug 1;38(29):2264-2276. doi: 10.1093/eurheartj/ehx162.
4
Rhabdomyolysis: pathogenesis, diagnosis, and treatment.横纹肌溶解症：发病机制、诊断与治疗
Ochsner J. 2015 Spring;15(1):58-69.
5
Safety of statins: an update.他汀类药物的安全性：更新。
Ther Adv Drug Saf. 2012 Jun;3(3):133-44. doi: 10.1177/2042098612439884.
6
Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation.泛硫乙胺，一种维生素B5的衍生物，可有效改变适合他汀类药物治疗的低至中度心血管风险受试者的总胆固醇、低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇：一项三盲、安慰剂对照和饮食控制的研究。
Vasc Health Risk Manag. 2014 Feb 27;10:89-100. doi: 10.2147/VHRM.S57116. eCollection 2014.
7
Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy.单独使用或与他汀类药物联合使用时，改性聚戊烯醇并不能降低高脂血症患者的血浆脂蛋白水平。
Lipids. 2011 Oct;46(10):923-9. doi: 10.1007/s11745-011-3591-8. Epub 2011 Jul 8.
8
An effective assessment of simvastatin-induced toxicity with NMR-based metabonomics approach.基于 NMR 代谢组学方法评估辛伐他汀诱导的毒性的有效性。
PLoS One. 2011 Feb 22;6(2):e16641. doi: 10.1371/journal.pone.0016641.
9
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.超越低密度脂蛋白胆固醇的思考：进一步降低心血管风险的策略
Vasc Health Risk Manag. 2009;5:793-9. doi: 10.2147/vhrm.s5684. Epub 2009 Sep 24.
10
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.肥胖、代谢综合征和 2 型糖尿病流行：二、致动脉粥样硬化性血脂异常的治疗管理。
J Clin Hypertens (Greenwich). 2009 Sep;11(9):520-7. doi: 10.1111/j.1559-4572.2009.00060.x.